Please login to the form below

Not currently logged in
Email:
Password:

FDA clears first therapy for rare childhood cancer

United Therapeutics’ Unituxin approved for neuroblastoma

FDA headquarters White Oak 

United Therapeutics' Unituxin has become the first-ever therapy approved in the US for neuroblastoma, a rare form of cancer that most commonly occurs in young children.

There are around 650 new cases of neuroblastoma diagnosed in the US every year, with long-term survival - even with aggressive therapy - in just 40% to 50% of patients, according to the FDA.

Neuroblastoma is the second most common solid tumour in childhood (after brain cancer), and it makes up around 8% of the total number of children's cancers.

The cancer affects immature nerve cells called neural crest cells and is typically diagnosed when children are under five years of age. The tumours most commonly occur in the adrenal glands or innerve tissue that runs along the spinal cord, and in some cases can spread to other tissues such as the bone marrow, bone, lymph nodes or skin.

At the moment treatment has focused on surgery of tumours that have not spread - which can often be curative - with intensive chemotherapy and radiotherapy used if the disease is more extensive. 

Unituxin (dinutuximab) is an anti-GD2 antibody that binds to a glycolipid antigen on the surface of neuroblastoma cells and has been approved by the FDA for use in combination with a cocktail of immune-stimulating drugs in high-risk patients who have responded at last partially to first-line therapy.

The drug was filed for approval in Europe at the end of 2013 but has not yet been cleared by the EMA, with a verdict expected in the next few weeks, according to United Therapeutics' co-chief executive Roger Jeffs.

Giving Unituxin alongside granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) helps direct an immune response against the tumour cells, according to United.  The drug is also a first because it is the first approved therapy that targets a non-protein antigen on cancer cells.

The safety and efficacy of Unituxin were tested in a 226-patient study whose tumours shrank after surgery and multidrug chemotherapy, along with radiotherapy and a bone marrow transplant.

Three years after treatment assignment, 63% of participants receiving the Unituxin combination were alive and free of tumour growth or recurrence, compared to 46% of participants treated with RA alone.

"Unituxin fulfils a critical need by providing a treatment option that prolongs survival in children with high-risk neuroblastoma," said Richard Pazdur, who heads the FDA's Office of Hematology and Oncology Products.

The therapy is not without its side effects, however, with most patients experiencing pain resulting from irritation of the nerve cells that generally requires intravenous opioid analgesics.

Article by
Phil Taylor

11th March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...